Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport in Anal Fissure
NCT00210444Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jun 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of abobotulinumtoxinA in anal fissure (2 arms), sponsored by Ipsen. Primary endpoint: Healing of the anal fissure. Started Jun 2003; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
anal fissure
Beyond the preview
Go deeper on NCT00210444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210444.